Mercuri, et al.; “Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections”; Antiviral Research, 2025
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-01-28 03:56:112025-01-28 03:56:11Mercuri, et al.; “Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections”; Antiviral Research, 2025
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-01-28 03:55:002025-01-28 03:55:28Mercuri, et al.; “Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology”; ERJ Open Res 2024
Tal-Singer, et al; “The COPD Foundation’s COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral Respiratory Infections“; Journal of Patient Experience, 2023
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2023-01-26 09:00:352024-10-22 14:32:04The COPD Foundation’s COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral Respiratory Infections
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2021-02-09 09:00:212024-10-22 14:47:57TLR-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs.
Proud et al; “Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model“; EBioMedicine, 2020
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2020-12-03 09:00:232024-10-22 14:46:21Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2015-07-21 09:00:432024-10-22 14:55:14Reducing the impact of influenza-associated secondary pneumococcal infections
Mifsud et al; “Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys“; Front Immunol, 2015
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2015-06-05 09:00:582024-10-22 14:52:44Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2012-07-23 09:00:342024-10-22 14:57:44Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice
Mercuri, et al.; “Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections”; Antiviral Research, 2025
Mercuri, et al.; “Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections”; Antiviral Research, 2025
https://doi.org/10.1016/j.antiviral.2024.106063
Mercuri, et al.; “Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology”; ERJ Open Res 2024
Mercuri, et al.; “Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology”; ERJ Open Res 2024
https://doi.org/10.1183/23120541.00199-2024
The COPD Foundation’s COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral Respiratory Infections
Tal-Singer, et al; “The COPD Foundation’s COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral Respiratory Infections“; Journal of Patient Experience, 2023
https://doi.org/10.1177/23743735231151554
TLR-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs.
Deliyannis et al; “TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs“; JCI Insight, 2021
https://doi.org/10.1172/jci.insight.140267
TLR2-mediated innate immune priming boosts lung anti-viral immunity
Girkin et al; “TLR2-mediated innate immune priming boosts lung anti-viral immunity“; European Respiratory Journal, 2020
https://doi.org/10.1183/13993003.01584-2020
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
Proud et al; “Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model“; EBioMedicine, 2020
https://doi.org/10.1016/j.ebiom.2020.103153
Reducing the impact of influenza-associated secondary pneumococcal infections
Mifsud et al; “Reducing the impact of influenza-associated secondary pneumococcal infections“; Immunol. Cell Biol, 2015
https://doi.org/10.1038/icb.2015.71
Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys
Mifsud et al; “Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys“; Front Immunol, 2015
https://doi.org/10.3389/fimmu.2015.00290
Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice
Tan et al; “Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice“; Mol. Pharm, 2012
https://doi.org/10.1021/mp300257x